RAPIDe-3 In partnership with about 75 other institutions across the globe, the practice of Dr. Raffi Tachdjian is currently participating in the RAPIDe-3 study on hereditary angioedema (HAE) type 1 and type 2. The purpose of this study is to evaluate the efficacy and safety of an oral investigational drug,…
Sponsored Content
Recent Posts
- Biocryst to present new Orladeyo, navenibart data at AAAAI meeting
- Real world study in Canada shows Takhzyro cuts HAE attacks by 80%
- Guest Voice: Why misconceptions about HAE are harmful
- Living with chronic illness changed my programming
- Rare form of HAE may bring more frequent attacks, greater daily impact